BR112021016102A2 - Moléculas de ligação a fcmr e usos das mesmas - Google Patents

Moléculas de ligação a fcmr e usos das mesmas

Info

Publication number
BR112021016102A2
BR112021016102A2 BR112021016102A BR112021016102A BR112021016102A2 BR 112021016102 A2 BR112021016102 A2 BR 112021016102A2 BR 112021016102 A BR112021016102 A BR 112021016102A BR 112021016102 A BR112021016102 A BR 112021016102A BR 112021016102 A2 BR112021016102 A2 BR 112021016102A2
Authority
BR
Brazil
Prior art keywords
fcmr
binding molecules
antibodies
pharmaceutical compositions
cancer
Prior art date
Application number
BR112021016102A
Other languages
English (en)
Portuguese (pt)
Inventor
M Mason Jacqueline
R Bray Mark
Richard Brokx
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of BR112021016102A2 publication Critical patent/BR112021016102A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021016102A 2019-02-15 2020-02-14 Moléculas de ligação a fcmr e usos das mesmas BR112021016102A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806237P 2019-02-15 2019-02-15
PCT/CA2020/050195 WO2020163962A1 (en) 2019-02-15 2020-02-14 Fcmr-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
BR112021016102A2 true BR112021016102A2 (pt) 2021-11-09

Family

ID=72043773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016102A BR112021016102A2 (pt) 2019-02-15 2020-02-14 Moléculas de ligação a fcmr e usos das mesmas

Country Status (14)

Country Link
US (1) US12286476B2 (https=)
EP (1) EP3924388A4 (https=)
JP (1) JP2022520817A (https=)
KR (1) KR20210139273A (https=)
CN (1) CN113993895A (https=)
AU (1) AU2020222408A1 (https=)
BR (1) BR112021016102A2 (https=)
CA (1) CA3130225A1 (https=)
EA (1) EA202192254A1 (https=)
IL (1) IL285585A (https=)
MX (1) MX2021009767A (https=)
SG (1) SG11202108837WA (https=)
TW (1) TWI857009B (https=)
WO (1) WO2020163962A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009767A (es) 2019-02-15 2021-11-17 Univ Health Network Moleculas de union de fmcr y usos de las mismas.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
CA2867444C (en) * 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
EP2970451A1 (en) * 2013-03-14 2016-01-20 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
US9493561B2 (en) * 2013-07-03 2016-11-15 University Health Network Antibodies to Toso
AU2015225867B2 (en) * 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
US20180201676A1 (en) 2015-02-11 2018-07-19 University Health Network Methods and compositions for modulating lilr proteins
ES2690420T3 (es) * 2015-05-28 2018-11-20 Universität Zu Köln Receptor de antígeno quimérico anti-toso y su uso
WO2018119425A2 (en) 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
MX2021009767A (es) 2019-02-15 2021-11-17 Univ Health Network Moleculas de union de fmcr y usos de las mismas.

Also Published As

Publication number Publication date
EP3924388A1 (en) 2021-12-22
SG11202108837WA (en) 2021-09-29
US12286476B2 (en) 2025-04-29
EP3924388A4 (en) 2023-02-15
JP2022520817A (ja) 2022-04-01
EA202192254A1 (ru) 2021-11-29
CA3130225A1 (en) 2020-08-20
TWI857009B (zh) 2024-10-01
AU2020222408A1 (en) 2021-09-09
MX2021009767A (es) 2021-11-17
US20220089725A1 (en) 2022-03-24
KR20210139273A (ko) 2021-11-22
TW202035461A (zh) 2020-10-01
WO2020163962A1 (en) 2020-08-20
IL285585A (en) 2021-09-30
CN113993895A (zh) 2022-01-28

Similar Documents

Publication Publication Date Title
CO2023004252A2 (es) Anticuerpos anti-ceacam5 y conjugados y usos de los mismos
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
CL2024003895A1 (es) Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso.
BR112019010943A2 (pt) métodos para o tratamento do câncer compreendendo agentes de ligação a tigit
CO2022002001A2 (es) Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
CO2018014010A2 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
UY31478A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
SA523440623B1 (ar) أجسام مضادة
BR112019005944A2 (pt) anticorpos que se ligam à interleucina 2 e usos dos mesmos
AR104484A1 (es) Anticuerpos anti-psma como agentes terapéuticos
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
BR112021025699A2 (pt) Anticorpos anti-mesotelina e imunoconjugados dos mesmos
BR112018000909A2 (pt) imunoconjugados de il22
BR112021017810A2 (pt) Anticorpos tsg-6 e usos dos mesmos
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos
BR112023018378A2 (pt) Moléculas de ligação a lilrb1 e lilrb2 e usos para as mesmas